Genflow Biosciences PLC Announces Total Voting Rights
-
NBA bans Mitchell, Champagnie one game for sparking melee
-
'Project Hail Mary' rockets to top of N. America box office
-
Syrians protest alcohol sale limits, curbs on personal freedom
-
Spurs can '100 percent' avoid nightmare of relegation: Saltor
-
Araujo header scrapes Liga leaders Barcelona win over Rayo
-
Israel launches strikes as Lebanon warns of invasion
-
Torrential rains in Kenya kill 81 in March: officials
-
Iran threatens Mideast infrastructure after Trump ultimatum
-
Spurs felled by Forest in relegation battle, Sunderland shock Newcastle
-
Spurs collapse against Forest, failing acid test
-
US may 'escalate to de-escalate' against Iran: Treasury chief
-
Howe disappointed in himself after 'painful' Newcastle defeat
-
Quansah to miss England's pre-World Cup friendlies
-
Araujo header scrapes Liga leaders Barca win over Rayo
-
Georgia buries Patriarch Ilia II as succession stirs fears of Russian influence
-
DeChambeau wins back-to-back LIV Golf play-offs
-
Sunderland inflict more derby pain on Newcastle
-
Nepali youth demand release of govt report into deadly September uprising
-
US, Iran trade threats to target infrastructure in Middle East
-
Paris doubles up with super-G victory at World Cup finals
-
Dortmund part ways with sporting director Kehl
-
Russia resumes use of space launch site damaged in accident
-
Cuba scrambles to restore power after new blackout
-
Senegal's Idrissa Gueye ready to 'hand back' AFCON medals
-
New Zealand's Walsh bags fourth world indoor gold
-
Goggia claims first super-G title after victory in Kvitfjell
-
Slovenia votes in tight polls, with conservatives eyeing comeback
-
A herd stop: Train kills 3 rare bison in Poland
-
Vietnam, Russia to sign energy deal: Hanoi
-
American Gumberg triumphs in Hainan for second DP World Tour win
-
South Africa clinch 19-run win over New Zealand in fourth T20
-
Iran threatens Middle East infrastructure after Trump ultimatum
-
French elect mayors in key cities including Paris
-
'They beat us with whips': Sudan RSF detainees tell of horrors in El-Fasher
-
Australia's Hannah Green wins historic third tournament in a row
-
China's premier vows to expand global 'trade pie': state media
-
Belgium commemorates Brussels attacks 10 years on
-
Sri Lanka raises fuel prices by 25 percent as war bites
-
Rights groups fear use of arrest to stifle free speech in Pakistan
-
Iranian missiles sow panic, destruction in Israeli towns
-
Damaged Russian tanker to be towed to Libya: state-owned company
-
Gilgeous-Alexander scores 40, LeBron breaks NBA appearance record
-
Cuba hit by second nationwide blackout in a week
-
BTS draws over 100,000 fans to Seoul comeback concert: label
-
US-China 'Board of Trade' may help ties but experts flag market worries
-
Sinner, defending champ Mensik advance to third round at Miami Open
-
Iran missile strikes wound over 100 in two south Israel towns
-
Hannah Green Secures Hat Trick with Statement Win at Australian Women's PGA Championship
-
6 Reasons Why FR Clothing Is Nonnegotiable in Construction Uniform Services
-
How to Cut Unnecessary Expenses Without Sacrificing Comfort
Genflow Biosciences PLC Announces Total Voting Rights
LONDON, UK / ACCESS Newswire / October 31, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, announces that the total issued share capital of the Company as at 31 October 2025 consists of 493,547,942 Ordinary Shares none of which are held in treasury. Therefore, the total number of voting rights in the Company is 493,547,942.
The figure of 493,547,942 Ordinary Shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there are no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
-Ends-
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
J.Oliveira--AMWN